GC
SCLN

Guggenheim Capital’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Guggenheim Capital’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-169,952
Closed -$1.9M – 2915
2017
Q3 		$1.9M Sell
169,952
-76,079
-31% -$839K ﹤0.01% 1710
2017
Q2 		$2.71M Buy
246,031
+80,709
+49% +$807K 0.01% 1411
2017
Q1 		$1.62M Sell
165,322
-19,500
-11% -$195K ﹤0.01% 1802
2016
Q4 		$2M Buy
+184,822
New +$1.85M 0.01% 1688

Guggenheim Capital's SCLN Position: Q4 2017 in Review

Guggenheim Capital sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 169,952 shares — an estimated $1.9M sold.

Guggenheim Capital first reported a position in SCLN in Q4 2016 and held it in 4 quarters. The position peaked at $2.71M in Q2 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

  • Guggenheim Capital reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Guggenheim Capital sold 169,952 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $1.9M.
  • Guggenheim Capital first reported a position in Sciclone Pharmaceuticals Inc in Q4 2016 and held it in 4 quarters.
  • Guggenheim Capital's Sciclone Pharmaceuticals Inc position peaked at $2.71M in Q2 2017.
  • 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on Guggenheim Capital's 13F filing for Q4 2017, filed 14 Feb 2018.